ADCT Healthcare

ADC Therapeutics SA

$1.55+0.65%

Price as of close on Nov 3, 2026 · Financials updated Oct 31, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Switzerland
Market cap: 197.9M USD
Enterprise value: 417.0M USD
Full-time employees: 188

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.86 vs a peer median of 0.63)higher risk: bigger price swings (beta 1.86 vs peers 0.63)

Ranks #1,146 of 1,157 healthcare companies (bottom 2%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
ADC Therapeutics's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Shareholders being diluted. Shares outstanding up 58% from December 2022 to August 2026.
ADC Therapeutics had 58% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.ADC Therapeutics had 58% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, ADC Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
ADC Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

10/ 100

Oct 5 10 → Nov 4 10

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-50.3%

SEC filings (IFRS mapped) · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-22.5%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-53.1%

SEC filings (IFRS mapped) · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-118.4%

SEC filings (IFRS mapped) · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

17/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-24.4%

SEC filings (IFRS mapped) · 3 years to Jun 2026Reported value33% base weight · Z-score -3.60Sector median: 0.0584 · MAD: 0.0840

Revenue growth3.0%

SEC filings (IFRS mapped) · 12 months to Jun 2026Reported value33% base weight · Z-score -0.31Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

13/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-125.1%

SEC filings (IFRS mapped) · 12 months to Jun 2026Reported value33% base weight · Z-score -10.86Sector median: 0.0706 · MAD: 0.1217

Return on assets-34.7%

SEC filings (IFRS mapped) · 12 months to Jun 2026Reported value33% base weight · Z-score -6.77Sector median: 0.0166 · MAD: 0.0537

Return on invested capitalUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin-11.6%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.86

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -3.66Sector median: 0.6250 · MAD: 0.3380

Current ratio3.03×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score 0.32Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about ADC Therapeutics

Is ADC Therapeutics getting weaker?: Its latest SEC filing (Aug 13, 2026) showed no major changes. Its overall score is unchanged at 10/100 since Oct 28, 2026.
How is ADC Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -50.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -50.3% vs peers 1.5% (weaker than 100% of peers).
Is ADC Therapeutics growing?: More slowly than most of its peers. Growth scores 17/100 against 1,393 healthcare peers. 3-year revenue growth -24.4% vs a peer median of 5.8% (weaker than 95% of peers).3-year revenue growth -24.4% vs peers 5.8% (weaker than 95% of peers).
How profitable is ADC Therapeutics?: Less profitable than most of its peers. Profitability scores 13/100 against 1,393 healthcare peers. Operating margin -125.1% vs a peer median of 7.1% (weaker than 88% of peers).Operating margin -125.1% vs peers 7.1% (weaker than 88% of peers).
How risky is ADC Therapeutics?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.86 vs a peer median of 0.63 (weaker than 93% of peers).Beta 1.86 vs peers 0.63 (weaker than 93% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 13, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: ADC Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	79.2M USD	79.6M USD	+0.5%
Net income (12 months)	−137.0M USD	−96.9M USD	−29.3%
Operating margin	-149.4%	-125.1%	+24.3 pts
Free cash flow (12 months)	−114.6M USD	−102.3M USD	−10.7%
Cash	231.0M USD	219.1M USD	−5.2%
Shares outstanding	127.2M	127.7M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	95.9%	98.4%	96.4%	91.6%	92.9%	▲ 1.3 pts
Operating margin	-771.6%	-58.8%	-238.6%	-184.4%	-149.3%	▲ 35 pts
Net margin	-678.2%	-74.9%	-345.1%	-222.8%	-175.3%	▲ 48 pts
Return on assets (ROA)	-37.2%	-32.0%	-67.7%	-49.0%	-44.1%	▲ 4.9 pts
Return on equity (ROE)	-149.3%	-197.8%	—	—	—	—
Free cash flow margin	-698.2%	-66.2%	-175.3%	-176.0%	-173.8%	▲ 2.2 pts
Current ratio	7.10×	5.31×	4.97×	3.62×	4.37×	▲ 21%
Quick ratio	6.95×	5.16×	4.73×	3.59×	4.31×	▲ 20%
Debt to equity	0.61×	—	—	—	—	—
Interest coverage	-14.27×	-3.36×	-3.58×	-2.60×	-2.35×	▲ 9.6%

ADCT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.86 vs a peer median of 0.63)higher risk: bigger price swings (beta 1.86 vs peers 0.63)

Ranks #1,146 of 1,157 healthcare companies (bottom 2%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

ADC Therapeutics's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Shareholders being diluted. Shares outstanding up 58% from December 2022 to August 2026.

ADC Therapeutics had 58% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.ADC Therapeutics had 58% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, ADC Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

ADC Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about ADC Therapeutics

Is ADC Therapeutics getting weaker?

Its latest SEC filing (Aug 13, 2026) showed no major changes. Its overall score is unchanged at 10/100 since Oct 28, 2026.

How is ADC Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -50.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -50.3% vs peers 1.5% (weaker than 100% of peers).

Is ADC Therapeutics growing?

More slowly than most of its peers. Growth scores 17/100 against 1,393 healthcare peers. 3-year revenue growth -24.4% vs a peer median of 5.8% (weaker than 95% of peers).3-year revenue growth -24.4% vs peers 5.8% (weaker than 95% of peers).

How profitable is ADC Therapeutics?

Less profitable than most of its peers. Profitability scores 13/100 against 1,393 healthcare peers. Operating margin -125.1% vs a peer median of 7.1% (weaker than 88% of peers).Operating margin -125.1% vs peers 7.1% (weaker than 88% of peers).

How risky is ADC Therapeutics?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.86 vs a peer median of 0.63 (weaker than 93% of peers).Beta 1.86 vs peers 0.63 (weaker than 93% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

79.2M USD

79.6M USD

+0.5%

Net income (12 months)

−137.0M USD

−96.9M USD

−29.3%

Operating margin

-149.4%

-125.1%

+24.3 pts

Free cash flow (12 months)

−114.6M USD

−102.3M USD

−10.7%

Cash

231.0M USD

219.1M USD

−5.2%

Shares outstanding

127.2M

127.7M

+0.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

95.9%

98.4%

96.4%

91.6%

92.9%

▲ 1.3 pts

Operating margin

-771.6%

-58.8%

-238.6%

-184.4%

-149.3%

▲ 35 pts

Net margin

-678.2%

-74.9%

-345.1%

-222.8%

-175.3%

▲ 48 pts

Return on assets (ROA)

-37.2%

-32.0%

-67.7%

-49.0%

-44.1%

▲ 4.9 pts

Return on equity (ROE)

-149.3%

-197.8%

—

Free cash flow margin

-698.2%

-66.2%

-175.3%

-176.0%

-173.8%

▲ 2.2 pts

Current ratio

7.10×

5.31×

4.97×

3.62×

4.37×

▲ 21%

Quick ratio

6.95×

5.16×

4.73×

3.59×

4.31×

▲ 20%

Debt to equity

0.61×

—

Interest coverage

-14.27×

-3.36×

-3.58×

-2.60×

-2.35×

▲ 9.6%